TITLE

Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles

AUTHOR(S)
Andersson, Erik; Bergemalm, Daniel; Kruse, Robert; Neumann, Gunter; D’Amato, Mauro; Repsilber, Dirk; Halfvarson, Jonas
PUB. DATE
October 2017
SOURCE
PLoS ONE;10/05/2017, Vol. 12 Issue 10, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: Genetic and immunological data indicate that inflammatory bowel disease (IBD) are characterized by specific inflammatory protein profiles. However, the serum proteome of IBD is still to be defined. We aimed to characterize the inflammatory serum protein profiles of Crohn’s disease (CD) and ulcerative colitis (UC), using the novel proximity extension assay. Methods: A panel of 91 inflammatory proteins were quantified in a discovery cohort of CD (n = 54), UC patients (n = 54), and healthy controls (HCs; n = 54). We performed univariate analyses by t-test, with false discovery rate correction. A sparse partial least-squares (sPLS) approach was used to identify additional discriminative proteins. The results were validated in a replication cohort. Results: By univariate analysis, 17 proteins were identified with significantly different abundances in CD and HCs, and 12 when comparing UC and HCs. Additionally, 64 and 45 discriminant candidate proteins, respectively, were identified with the multivariate approach. Correspondingly, significant cross-validation error rates of 0.12 and 0.19 were observed in the discovery cohort. Only FGF-19 was identified from univariate comparisons of CD and UC, but 37 additional discriminant candidates were identified using the multivariate approach. The observed cross-validation error rate for CD vs. UC remained significant when restricting the analyses to patients in clinical remission. Using univariate comparisons, 16 of 17 CD-associated proteins and 8 of 12 UC-associated proteins were validated in the replication cohort. The area under the curve for CD and UC was 0.96 and 0.92, respectively, when the sPLS model from the discovery cohort was applied to the replication cohort. Conclusions: By using the novel PEA method and a panel of inflammatory proteins, we identified proteins with significantly different quantities in CD patients and UC patients compared to HCs. Our data highlight the potential of the serum IBD proteome as a source for identification of future diagnostic biomarkers.
ACCESSION #
125495845

 

Related Articles

  • Fenotipo e historia natural de la enfermedad inflamatoria intestinal en un centro de referencia en Medell�n-Colombia. Ba�os, Fabi�n Juliao; V�lez, Mario Hern�n Ruiz; Arango, Jos� Fernando Fl�rez; G�mez, Jorge Hernando Donado; Zuluaga, Juan Ignacio Mar�n; Arango, Claudia Monsalve; G�mez, Carlos Andr�s Jim�nez; Zapata, Yineth Agudelo; Velayos, Fernando S. // Revista Colombiana de Gastroenterolog�a;Jul2012, Vol. 25 Issue 3, p240 

    Worldwide the frequencies of inflammatory bowel disease, ulcerative colitis and Crohn�s disease have all increased. In our own environment it has become necessary to establish the epidemiology of these entities and to determine their clinical and endoscopic behavior. Methodology: This is a...

  • In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Bridger, S.; Lee, J.C.W.; Bjarnason, I.; Lennard Jones, J.E.; Macpherson, A.J. // Gut;Jul2002, Vol. 51 Issue 1, p21 

    Background and aims: Smoking tobacco has opposite effects on the different forms of inflammatory bowel disease (IBD). It predisposes to the development of Crohn's disease (CD) yet is associated with a reduced incidence of ulcerative colitis (UC). We have studied sib pairs discordant for both...

  • Inflammatory bowel disease. O'Malley, John; Spinks, Julian // Pulse;5/25/2011, Vol. 71 Issue 19, p16 

    The article presents questions and answers related to irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), including the diagnostic process of IBD, what drug therapy to treat Crohn's disease, and the risk of cancer with ulcerative colitis.

  • Inflammatory bowel diseases.  // Mayo Clinic Health Letter;Oct2001, Vol. 19 Issue 10, p1 

    Discusses inflammatory bowel diseases. Etiology; Difference between Crohn's disease and ulcerative colitis; Signs and symptoms; Diagnostic techniques; Cancer risks; Treatment strategies. INSET: Colon cancer risks..

  • Kallikrein-kinin system activation in Crohn’s disease: differences in intestinal and systemic markers Devani, Massimo; Cugno, Massimo; Vecchi, Maurizio; Ferrero, Stefano; Di Berardino, Federica; Avesani, Ettore Contessini; de Franchis, Roberto; Colman, Robert W. // American Journal of Gastroenterology;Aug2002, Vol. 97 Issue 8, p2026 

    OBJECTIVES:Observations in experimental models and in human ulcerative colitis suggest that activation of the kallikrein-kinin system plays a role in the pathogenesis of inflammatory bowel disease. The aim of this study was to assess activation of the plasma and tissue kallikrein-kinin system in...

  • Unlocking the secrets of IBD. SerVaas, Cory // Saturday Evening Post;Jan/Feb94, Vol. 266 Issue 1, p42 

    Presents interviews with seven inflammatory disease specialists. Case for cyclosporine; Tracing genetic links; Choosing the right treatment; Longevity, pregnancy and new drugs; Alternatives to lleostomy; Iron and IBD; What causes IBD? INSETS: Now in remission, by Patrick Perry.;A cse of the...

  • A population-based study of familial clustering of inflammatory bowel disease in Florence. Palli, Domenico; Saieva, Calogero; Trallori, Giacomo; Bardazzi, Gabrielle; D'albasio, Guiseppe; Milla, Monica; Galli, Monica; Tarantino, Ottaviano; Pacini, Franco // European Journal of Public Health;Mar1997, Vol. 7 Issue 1, p109 

    Presents a study that investigated familial clustering of inflammatory bowel disease (IBD) in Florence, Italy. Information on ulcerative colitis and Crohn's disease; IBD diagnosis; Methods used in the study; Results and discussion.

  • Inflammatory bowel disease. Veronesi, James // RN;May2003, Vol. 66 Issue 5, p38 

    Discusses two types of inflammatory bowel disease (IBD): Crohn's disease and ulcerative colitis. Common signs and symptoms; Theories on the role of the immune system in the development of IBD; Distinctions between Crohn's and ulcerative colitis; Medical management; Surgical intervention;...

  • Factors Affecting Surgical Risk in Elderly Patients With Inflammatory Bowel Disease Page, Michael J.; Poritz, Lisa S.; Kunselman, Susan J.; Koltun, Walter A. // Journal of Gastrointestinal Surgery;Jul2002, Vol. 6 Issue 4, p606 

    The operative treatment of elderly patients with inflammatory bowel disease (IBD) has often been avoided in favor of medical management because of a perceived increase in surgical risk. This study sought to define the following in the elderly IBD patient population: (1) the risk of surgical...

  • Psychosomatic Aspects. Pommer, Peter; Wehkamp, Jan; Götz, Martin; Herrlinger, Klaus; Steurer, Wolfgang; Stange, Eduard F. // Deutsches Aerzteblatt International;7/1/2016, Vol. 113 Issue 26, p462 

    A letter to the editor is presented in response to the article "Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis" by Jan Wehkamp and colleagues in a 2016 issue.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics